Details for New Drug Application (NDA): 062231
✉ Email this page to a colleague
NDA 062231 describes ERYTHROMYCIN ETHYLSUCCINATE, which is a drug marketed by Amneal Pharms, Ani Pharms, Cadila Pharms Ltd, Endo Operations, Alpharma Us Pharms, Dista, Naska, Parke Davis, Pharmafair, Aurobindo Pharma Usa, Azurity, and Barr, and is included in fourteen NDAs. It is available from five suppliers. Additional details are available on the ERYTHROMYCIN ETHYLSUCCINATE profile page.
The generic ingredient in ERYTHROMYCIN ETHYLSUCCINATE is erythromycin ethylsuccinate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin ethylsuccinate; sulfisoxazole acetyl profile page.
The generic ingredient in ERYTHROMYCIN ETHYLSUCCINATE is erythromycin ethylsuccinate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin ethylsuccinate; sulfisoxazole acetyl profile page.
Summary for 062231
| Tradename: | ERYTHROMYCIN ETHYLSUCCINATE |
| Applicant: | Parke Davis |
| Ingredient: | erythromycin ethylsuccinate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062231
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | EQ 200MG BASE/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | EQ 400MG BASE/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
